What Do Analysts Say About Corbus Pharmaceuticals Holdings Inc (CRBP)?

Rosalind Gate

Corbus Pharmaceuticals Holdings Inc (CRBP) saw an uptrend of 1.84% in the recent trading with $8.32 being its most recent. The current price level -59.53% lower than the highest price of $20.56 marked by the stock while trading over the past 52-weeks, whereas it is 79.31% higher than the lowest price of $4.64 the company dropped to over past 52-weeks. The latest news story on CRBP appeared in (GlobeNewswire) under the title “Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference”.

Do analysts rate it as a buy, sell or hold?

Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.

Corbus Pharmaceuticals Holdings Inc Earnings – What Happened With CRBP

Coming around sales and income figures on CRBP Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Corbus Pharmaceuticals Holdings Inc (CRBP) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 38.04% for net revenue.

CRBP – Corbus Pharmaceuticals Holdings Inc Stock Earnings Estimates

The perspective of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP),s current quarter earnings identifies that analysts are in consensus over the estimate of -1.26 for stock,s EPS in the current quarter. Corbus Pharmaceuticals Holdings Inc (CRBP) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 38.04% for net revenue. Company,s EPS for the last quarter was -0.78.

Corbus Pharmaceuticals Holdings Inc – Insider Activity and Holdings

Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 17.55 million. CRBP does have institutional investors; and they hold 55.95% of the stock.

Key Metrics for CRBP

The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Corbus Pharmaceuticals Holdings Inc has a debt to equity ratio of 0.02.

Baxter Report
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.